Overslaan en naar de inhoud gaan

 Wetenschapelijke artikelen

A Technologist’s guide, radiopharmacy: an update. Chapter 2: Theoretical Basics of Radiopharmacy, Zéna Wimana, 18-29.

Auteurs : Wimana Z
Jaar : 2019
Journal : Book
Volume : chapter 2
Pagina's : 18-29

68Ga-PSMA PET/CT-based metastasis-directed radiotherapy for oligometastatic prostate cancer recurrence after radical prostatectomy.

Auteurs : Artigas C, Flamen P, Charlier F, Levillain H, Wimana Z, Diamand R, Albisinni S, Gil T, Velthoven Rv, Peltier A, Van Gestel D, Roumeguere T, Otte FX
Jaar : 2019
Journal : World J Urol
Volume : 37
Pagina's : 1535-1542

Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle.

Auteurs : Bartelink IH, Jones EF, Shahidi-Latham SK, Lee PRE, Zheng Y, Vicini P, van t Veer L, Wolf D, Iagaru A, Kroetz DL, Prideaux B, Cilliers C, Thurber GM, Wimana Z, Gebhart G
Jaar : 2019
Journal : Clin Pharmacol Ther
Volume : 106
Pagina's : 148-163

A dosimetry procedure for organs-at-risk in <sup>177</sup>Lu peptide receptor radionuclide therapy of patients with neuroendocrine tumours.

Auteurs : Marin G, Vanderlinden B, Karfis I, Guiot T, Wimana Z, Reynaert N, Vandenberghe S, Flamen P
Jaar : 2018
Journal : Phys Med
Volume : 56
Pagina's : 41-49

N-Acetylcysteine breaks resistance to trastuzumab caused by MUC4 overexpression in human HER2 positive BC-bearing nude mice monitored by 89Zr-Trastuzumab and 18F-FDG PET imaging.

Auteurs : Wimana Z, Gebhart G, Guiot T, Vanderlinden B, Larsimont D, Doumont G, Van Simaeys G, Goldman S, Flamen P, Ghanem G
Jaar : 2017
Journal : Oncotarget
Volume : 8(34)
Pagina's : 56185-56198

Accuracy and precision assessment for activity quantification in individualized dosimetry of 177Lu-DOTATATE therapy.

Auteurs : Marin G, Vanderlinden B, Karfis I, Guiot T, Wimana Z, Flamen P, Vandenberghe S
Jaar : 2017
Journal : EJNMMI Phys
Volume : 4
Pagina's : 7

Value of the 68Ga-DOTATATE PET-CT in the diagnosis of endometriosis. A pilot study.

Auteurs : Fastrez M, Artigas C, Sirtaine N, Wimana Z, Caillet M, Rozenberg S, Flamen P
Jaar : 2017
Journal : Eur J Obstet Gynecol Reprod Biol
Volume : 212
Pagina's : 69-74

N-Acetylcysteine breaks resistance to trastuzumab caused by MUC4 overexpression in human HER2 positive BC-bearing nude mice monitored by 89Zr-Trastuzumab and 18F-FDG PET imaging.

Auteurs : Wimana Z, Gebhart G, Guiot T, Vanderlinden B, Larsimont D, Doumont G, Van Simaeys G, Goldman S, Flamen P, Ghanem G
Jaar : 2017
Journal : Oncotarget

Paget bone disease demonstrated on 68Ga-PSMA ligand PET/CT.

Auteurs : Artigas C, Alexiou J, Garcia C, Wimana Z, Otte FX, Gil T, Van Velthoven R, Flamen P
Jaar : 2016
Journal : Eur J Nucl Med Mol Imaging
Volume : 43(1)
Pagina's : 195-6

Imaging Diagnostic and Therapeutic Targets: Human Epidermal Growth Factor Receptor 2.

Auteurs : Gebhart G, Flamen P, de Vries EG, Jhaveri K, Wimana Z
Jaar : 2016
Journal : J Nucl Med
Volume : 57 Suppl 1
Pagina's : 81S-8S

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR Trial.

Auteurs : Gebhart G, Lamberts LE, Wimana Z, Garcia C, Emonts P, Ameye L, Stroobants S, Huizing M, Aftimos P, Tol J, Oyen WJ, Vugts DJ, Hoekstra OS, Schröder CP, Menke-van der Houven van Oordt CW, Guiot T, Brouwers AH, Awada A, de Vries EG, Flamen P
Jaar : 2016
Journal : Ann Oncol
Volume : 27(4)
Pagina's : 619-24

Mucolytic Agents Can Enhance HER2 Receptor Accessibility for [(89)Zr]Trastuzumab, Improving HER2 Imaging in a Mucin-Overexpressing Breast Cancer Xenograft Mouse Model.

Auteurs : Wimana Z, Gebhart G, Guiot T, Vanderlinden B, Morandini R, Doumont G, Sherer F, Van Simaeys G, Goldman S, Ghanem G, Flamen P
Jaar : 2015
Journal : Mol Imaging Biol
Volume : 17(5)
Pagina's : 697-703